USPTO awards Transcept Pharmaceuticals patent covering Intermezzo's composition and usage method

Download PDF Copy

Feb 10 2010

NewsGuard 100/100 Score

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that the first patent covering the composition and method of use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office. Transcept announced the issuance of a Notice of Allowance for claims under the application for this patent, U.S. Patent Application Serial No. 11/060,641, on December 14, 2009. The newly issued patent, U.S. Patent No. 7,658,945, titled "Compositions for Delivering Hypnotic Agents Across the Oral Mucosa and Methods of Use Thereof," will expire no earlier than February 2025.

SOURCE Transcept Pharmaceuticals, Inc.

Posted in: Medical Patent News | Pharmaceutical News

Tags: Neuroscience, New Drug Application, Pharmaceuticals, Sleep

Comments (0)

Download PDF Copy

Suggested Reading

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

New biomarkers offer hope for early detection and prevention of Alzheimer's

New biomarkers offer hope for early detection and prevention of Alzheimer's

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Urine RNA analysis shows promise for detecting genitourinary diseases